Navigation Links
CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients
Date:11/21/2008

ave psoriasis(2), a distressing chronic inflammatory disease. Approximately 80 per cent of these patients have plaque psoriasis, which is characterised by red, scaly patches.(3) Psoriasis can be extremely distressing, and may have a significant impact on patients' quality of life. It is a condition which is frequently physically and psychologically disabling.(4)

Currently, treatments for children and adolescents with psoriasis are mainly limited to topical medications that are applied directly to the skin. Whilst these treatments may be effective at reducing the visible skin lesions and associated symptoms, they are generally used for mild and moderate forms of paediatric psoriasis.

Enbrel is an innovative drug that works by reducing the chronic inflammation that leads to plaque psoriasis.

To access further media information relating to this press release, additional information on Enbrel and future media announcements, please register on the media centre athttp://www.wyeth.eu. If you subscribe to receive our emails you will get updates as soon as new content added to the site. Please note you will be able to unsubscribe at any time and we will not pass your details to any third party.

Notes To Editors

"The 211 study: Enbrel(R) in children and adolescents(5)

The 48 week study involved 211 patients with moderate-to-severe psoriasis aged four to 17 years. During the first 12 weeks of the trial, patients received once weekly injections of either placebo or 0.8 mg of Enbrel per kilogram of body weight up to a maximum of 50 mg. For the next 24 consecutive weeks, all patients went on to receive Enbrel. The 138 patients still participating at week 36 were then re-randomised to receive either placebo or Enbrel in order to investigate whether stopping treatment would lead to any rebound.

At week 12, almost tw
'/>"/>

SOURCE Wyeth Pharmaceuticals Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Task Force Recommends Screening for Hearing Loss in All Newborns
2. FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis
3. FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent
4. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
5. CHMP Recommends Expanded Use of Angiox(R) (Bivalirudin) in Europe for Patients With Acute Coronary Syndromes
6. Tibotec Data Presented at ICAAC and HIV9 Follow Key Regulatory Approvals for Anti-HIV Compounds
7. Berlin Hearts EXCOR(R) Pediatric Receives Unconditional Investigational Device Exemption (IDE) Approval
8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
9. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
10. Sunshine Heart Announces IDE Approval To Begin C-Pulse U.S. Clinical Feasibility Trial
11. Nexgen Spine Receives CE Mark Approval for the Physio-L(R) Artificial Disc
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... July 2, 2015 Releases of ... Aedes aegypti , , reduced the dengue ... Brazil by 95%, well below the modelled ... http://photos.prnewswire.com/prnh/20150630/227348LOGO) , The journal PLOS Neglected Tropical ... Oxitec,s genetically engineered mosquitoes. The results showed that in ...
(Date:7/2/2015)... , July 2, 2015   EVO Aesthetic ... the leading provider for non-invasive aesthetics in ... tattoo removal treatments with the Astanza Duality laser. The ... well being through various medical and laser procedures. Their ... unwanted ink a clear solution to their tattoo regret. ...
(Date:7/2/2015)... DURHAM, N.C. , July 2, 2015 ... its acquisition of assets related to the ion channel ... that had previously been obtained as part of Pfizer,s ... all of Pfizer,s rights to the "Icagen" name and ... will provide comprehensive services for ion channel and transporter ...
Breaking Medicine Technology:Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 2Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 3EVO Offers Advanced Laser Tattoo Removal With Astanza Duality In Lakeway, TX 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 4
... , ... a new market research report is available in its ... Market Review , http://www.reportlinker.com/p0164247/Insulin-Pumps-External---A-World-Market-Review.html , Insulin ... better control over diabetes, when compared to other forms ...
... , BELLEVUE, Wash., Dec. 1 ... retailer of health, beauty, vision, and pharmacy products, today announced ... orders were the highest in company history. This holiday season ... featured more special offers than in previous years and their ...
Cached Medicine Technology:Reportlinker Adds Insulin Pumps (External) - A World Market Review 2Reportlinker Adds Insulin Pumps (External) - A World Market Review 3Reportlinker Adds Insulin Pumps (External) - A World Market Review 4drugstore.com, inc. Has Best Day Ever on Cyber Monday 2drugstore.com, inc. Has Best Day Ever on Cyber Monday 3
(Date:7/3/2015)... ... July 03, 2015 , ... Renowned rhinoplasty surgeon and Symposium Chairman, ... Dallas Rhinoplasty Symposium . To be held from March 4th - 6th, the 2016 ... the Westin Galleria Dallas. , Designed to take participants from the basic training and ...
(Date:7/3/2015)... ... July 03, 2015 , ... ... healthcare providers, has been retained to lead a national chief nursing officer ... top-ranked executive search firms in the healthcare industry, B. E. Smith has recently ...
(Date:7/3/2015)... ... 2015 , ... Smoothies are all the rage right now and all you ... ingredients. Aurora Natural is proud to introduce a new line of all natural products ... vitamins and minerals! , Aurora is offering a variety of blends and stand-alone items ...
(Date:7/3/2015)... TX (PRWEB) , ... July 03, 2015 , ... Jennifer ... First Choice Emergency Room , the largest network of independent freestanding emergency rooms ... new facility medical director of our Sienna Plantation facility,” said Executive Medical Director of ...
(Date:7/3/2015)... ... July 03, 2015 , ... " Selfie on a Stick ” was ... and coolest technology products available to consumers. Amanda Forstrom, a technology expert and special ... are great for documenting memories. , Almost every smartphone has an incredibly powerful camera ...
Breaking Medicine News(10 mins):Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:Aurora Product, Inc. Announces An Original New Line: Smoothie Fixins’ 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 3Health News:Learn How to Take Selfies like Kendall Jenner 2
... Synovics,Pharmaceuticals, Inc. (OTC Bulletin Board: SYVC), a ... Report,with the Securities and Exchange Commission. Consolidated gross ... 2008 were $6,121,632 compared,to $5,713,761 for the same ... strong growth of the over-the-counter (OTC) product line ...
... based on successful,management of nearly 45,000 cases ... NEWPORT NEWS, Va., June 17 ... organization providing direct,case management services and healthcare ... and chronic diseases each year who are,unable ...
... ,magic bullet, to help miilions of children in ... News) -- A new compound that may lead to ... by researchers at the University of Texas Health Science ... especially important for developing countries, where diarrhea is a ...
... a doctor could get a lot longer if the current ... increase soon, according to a new University of Missouri study. ... the MU School of Medicine, and his research team found ... 44,000 family physicians and general internists in less than 20 ...
... blood tests for breast, ovarian cancers, HERNDON, ... (CIT), a state-chartered non-profit, announced today,that its GAP ... of Funds, made,a $100,000 early-stage investment in OTraces, ... accurate and sensitive blood screening,tests for breast and ...
... in less than 90 seconds ... Varian Medical Systems, DECATUR, Ill., June 17 Decatur ... third in the,United States, to treat a cancer patient using ... John Hosler, an,85-year-old prostate cancer patient, received his treatment in ...
Cached Medicine News:Health News:Synovics Pharmaceuticals Files Its Second Quarter, 2008 Form 10Q with the SEC 2Health News:Synovics Pharmaceuticals Files Its Second Quarter, 2008 Form 10Q with the SEC 3Health News:Synovics Pharmaceuticals Files Its Second Quarter, 2008 Form 10Q with the SEC 4Health News:Synovics Pharmaceuticals Files Its Second Quarter, 2008 Form 10Q with the SEC 5Health News:Patient Data Analysis Report Finds More Than 75 Percent of Chronically Ill Patients Unable to Obtain Needed Healthcare Have Some Form of Insurance 2Health News:Inexpensive Compound Could Treat Severe Diarrhea 2Health News:US could face shortage of 44,000 primary care physicians by 2025 2Health News:US could face shortage of 44,000 primary care physicians by 2025 3Health News:CIT GAP Funds Invests in OTraces, Inc. 2Health News:Decatur Memorial Hospital Becomes First in Illinois to Treat Cancer Patients With RapidArc(TM) Radiotherapy Technology 2Health News:Decatur Memorial Hospital Becomes First in Illinois to Treat Cancer Patients With RapidArc(TM) Radiotherapy Technology 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: